Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Mirtazapine Treatment of Social Phobia in Women: A Randomized, Double-Blind, Placebo-Controlled Study

Muehlbacher, Moritz MD*; Nickel, Marius K. MD* † ‡; Nickel, Cerstin MD; Kettler, Christian MD; Lahmann, Claas MD; Gil, Francisco Pedrosa MD§; Leiberich, Peter K. MD; Rother, Nadine; Bachler, Egon PhD; Fartacek, Reinhold MD*; Kaplan, Patrick MD*; Tritt, Karin PhD; Mitterlehner, Ferdinand Mag; Anvar, Javaid MD*; Rother, Wolfhardt K. MD; Loew, Thomas H. MD; Egger, Christoph MD*

Journal of Clinical Psychopharmacology: December 2005 - Volume 25 - Issue 6 - p 580-583
doi: 10.1097/01.jcp.0000186871.04984.8d
Brief Reports

Abstract: Social phobia is an anxiety disorder characterized by extreme fear and phobic avoidance of social and performance situations and by a relatively poor health-related quality of life. The goal of this study was to compare the efficacy of mirtazapine versus placebo in the treatment of patients with social phobia. In 2004, we conducted a randomized, double-blind, placebo-controlled study of mirtazapine in 66 female subjects from the general population meeting the criteria for social phobia. The subjects were randomly assigned in a 1:1 manner to mirtazapine (n = 33) or placebo (n = 33). The treatment lasted 10 weeks. Seven patients dropped out. Primary outcome measures were self-reported changes on the Social Phobia Inventory, Liebowitz Social Anxiety Scale, and Health Survey (SF-36). In comparison with the placebo group and according to the intent-to-treat principle, significant differences on the Social Phobia Inventory and Liebowitz Social Anxiety Scale scales (all P < 0.001), as well as on most (5 from 8) scales of SF-36 (all P < 0.001), were observed in the mirtazapine-treated subjects. All patients tolerated mirtazapine relatively well. Mirtazapine appears to be an effective agent in the treatment of social phobia in women and in the improvement of their health-related quality of life.

*University Clinic for Psychiatry 1, PMU, Salzburg, Austria; †Clinic for Psychosomatic Medicine, Inntalklinik, Simbach/Inn, Germany; ‡Department of Psychosomatic Medicine, University Clinic, Regensburg and §Psychosomatic Ambulance, Medicine Clinic, Ludwig-Maximilians University, Munich, Germany.

Received February 24, 2005; accepted after revision June 1, 2005.

Address correspondence and reprint requests to Marius Nickel, MD, Inntalklinik, 84359 Simbach am Inn, Germany. E-mail: m.nickel@inntalklinik.de.

© 2005 Lippincott Williams & Wilkins, Inc.